Europe PMC

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Psoriasis is a chronic inflammatory skin disease in which the IL-23/Th17/IL-17 axis plays a central pathogenic role while also contributing to antifungal defence. IL-17-targeting biologics such as secukinumab and ixekizumab are increasingly used in its management. This study aimed to characterize changes in the diversity and composition of oral fungal and bacterial communities in psoriasis patients before and after treatment with IL-17 inhibitors. Oral swabs were collected from psoriasis patient

Background Data on the prevalence of sensitive skin in patients with chronic inflammatory skin diseases are lacking. The aim of this study was to address this gap.Methods This observational study included patients with psoriasis, atopic dermatitis or chronic hand eczema who attended the Unit of Dermatology of Ferrara and Messina, Italy, between June and December 2023. All participants completed a 10-item questionnaire for the diagnosis of sensitive skin (score range: 0-10). Participants were cla

Background Psoriasis is a chronic immune-mediated skin disease influenced by genetic, environmental, and lifestyle factors, with increasing burden among working-age adults.Objective To examine global trends in psoriasis prevalence among working-age adults, evaluate associations with lifestyle factors using a simplified Life's Essential 4 (LE4) index, and explore potential dietary causal relationships through Mendelian randomization (MR).Methods Global prevalence trends from 1990 to 2021 were ana

Objective To disentangle tobacco constituents in psoriasis, we contrasted nicotine exposure-proxied by the nicotine metabolite ratio (NMR)-with smoking intensity (cigarettes per day, CPD) and evaluated cross-ancestry effects.Methods This study applied multivariable Mendelian randomization (MR) jointly modeling genetically proxied NMR (instrumented using variants from a European-ancestry GWAS) and CPD to estimate their independent effects on liability to psoriasis and psoriatic arthritis (PsA). C

Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or exacerbation of psoriasis under BCDT.Objectives This article aims to analyze clinical characteristics, treatment courses, and outcomes of MS patients who developed or experienced worsening of psoriasis during BCDT.Design This retrospective, multicenter analysis i

Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly

Abstract Background Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real-world practice remains unclear. Objectives To evaluate

[This corrects the article DOI: 10.1002/jvc2.70093.].Weiterlesen

Tobacco smoking is viewed as a behavioral risk factor for psoriasis initiation and progress, even among those undergoing biologic treatment. However, evidence regarding the association between tobacco smoking and treatment response to biologics among patients with psoriasis is limited. This study aimed to explore the impact of tobacco smoking on the efficacy of biologic treatment in patients with psoriasis. Patients with psoriasis undergoing biologic treatment were recruited from 2022 to 2024 at

No abstract supplied.Weiterlesen

Introduction The rising incidence of inflammatory skin diseases, including psoriasis, has necessitated new treatment approaches. This paper focuses on the development of a hibiscetin-impregnated nanogel that reduces the severity of skin inflammation.Methods Imiquimod (IMQ) was used to induce psoriasis-like inflammation in animal models, and the nanogel's worthiness was compared. Nanogel was prepared in different concentrations of hibiscetin, namely F1 (1) and F2 (2), and characterized in terms o

No abstract supplied.Weiterlesen

Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, dysregulated immune signaling and systemic comorbidities, affecting nearly 2-3% of the global population. Although conventional therapies have improved disease management, they remain limited by poor drug penetration, systemic toxicity, adverse effects, high costs and relapse after discontinuation. The distinctive pathophysiology of psoriatic skin, with its thickened stratum corne

Background Psoriasis is a chronic, inflammatory and systemic skin disease. Currently, none of the treatment can effectively prevent the recurrent of psoriasis. α-Hederin is the main active ingredient of the traditional Chineses medicine Ivy, which has been proven to have anti-inflammatory effects. However, its effects on psoriasis and mechanisms of action remain unclear.Objective This study aimed to investigate the effects of α-Hederin on murine psoriasis and its underlying mechanisms.Methods Th

No abstract supplied.Weiterlesen

The human gut microbiota is involved in immune regulation, metabolism, and skin homeostasis. In recent years, gut microbiota alterations have been linked with several inflammatory skin disorders, such as atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS). This systematic review synthesises current evidence on gut microbiota composition and functional alterations in these dermatoses. A comprehensive literature search was conducted in the PubMed database, identifying studies from

Background Durability of response to IL-17A blockade (secukinumab) varies, representing a major clinical challenge. Psoriasis is inherently linked to immunometabolic dysfunction. We hypothesized that simple, routine metabolic indices could predict long-term treatment stability, offering crucial pre-treatment stratification tools.Methods This was a 52-week prospective, single-center cohort study of 118 patients with moderate-to-severe plaque psoriasis initiating secukinumab. We defined Durable Re

Ethnopharmacological relevance The traditional Chinese herbal medicine called Xiao-bi decoction (XBD) has been used for decades to treat psoriasis, but its mechanism of action is poorly understood.Aim of the study To investigate the underlying mechanism of XBD against psoriasis using systematic pharmacological techniques.Materials and methods A psoriasis model was established in mice using imiquimod (IMQ). The efficacy of XBD was evaluated based on psoriasis severity scores and immune cell infil

Psoriasis affecting special anatomical sites (scalp, face, intertriginous areas, and genitals) poses unique treatment challenges and often shows inadequate responses. This study evaluates the real-world efficacy and safety of IL-17 inhibitors in treating psoriasis affecting special sites, and identifies clinical determinants for achieving PASI75 and PASI90 responses.A retrospective cohort of 1,469 patients receiving IL-17 therapy was analyzed.Generalized linear models, univariate and multivariat

Objective Individuals with psoriasis (PsO) or psoriatic arthritis (PsA) have an elevated risk of major adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardial infarction (MI), and cerebrovascular accident (CVA). Biologic disease-modifying antirheumatic drugs (bDMARDs) may reduce cardiovascular risk; however, whether MACE risk differs by bDMARD class for this population is unknown.Methods Using data from TriNetX database, we identified patients with PsO/PsA who wer

Background General Practitioners (GPs) act as primary gatekeepers for patients with psoriasis and their screening practice for cardiovascular disease (CVD) and psoriastic arhtiris (PsA) y. This study aimed to assess the awareness and screening routines of Danish GPs regarding CVD and PsA in patients with psoriasis.Methods A nationwide cross-sectional survey on screening practice was conducted involving 490 randomly selected Danish GPs. Data were analyzed descriptively based on 101 responses (21%